Adeno-associated vectors for enhanced transduction and reduced immunogenicity

US10081659B2 · kind B2 · utility

Assignees

• The United States of America as Represented by the Secretary, Dept. of Health and Human Services · US
• University of Florida Research Foundation, INC. · US

Inventors

• John A. Chiorini · Silver Spring, US
• Sandra Wainer · Bethesda, US
• Mavis Agbandje-McKenna · Gainesville, US
• Sujata Halder · Gainesville, US

Key dates

• Filing date: Apr 6, 2016
• Grant date: Sep 25, 2018
• Expiry date: Jun 24, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2810/6027
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A modified adeno-associated virus (AAV) capsid protein comprising at least one non-native amino acid that confers to the modified AAV particles new properties, such as increased transduction efficiency and reduced immunogenicity. These modified AAV proteins and particles are particularly useful for gene therapy and the treatment of various diseases and conditions.